Phaseline

Targets › SLC12A1

SLC12A1 (Solute carrier family 12 member 1): drug programs, companies and trials

20 programs from 17 companies in 21 trials: 11 Phase 4, 5 Phase 3, 3 Phase 1, 2 Phase 2; Cardiovascular, Oncology, Genitourinary; next expected readout Nov 2026.

Renal sodium, potassium and chloride non-electrogenic ion symporter that mediates the transepithelial NaCl reabsorption in the thick ascending limb and plays an essential role in the urinary concentration and volume regulation. It can substitute NH4(+) for K(+), enabling NH4(+) apical transmembrane transport in the medullary thick ascending limb (MTAL). (UniProt, Q13621)

Open in Phaseline: the race on SLC12A1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Heart Center Research, LLCBumetanide
Sodium-(potassium)-chloride cotransporter 2 inhibitor
SLC12A1Phase 4Heart Failure, CongestiveDec 2026
Heart Center Research, LLCFurosemide
Sodium-(potassium)-chloride cotransporter 2 inhibitor
SLC12A1Phase 4Heart Failure, CongestiveDec 2026
Heart Center Research, LLCTorsemide
Sodium-(potassium)-chloride cotransporter 2 inhibitor
SLC12A1Phase 4Heart Failure, CongestiveDec 2026
Morten H. BestleFurosemide
Sodium-(potassium)-chloride cotransporter 2 inhibitor
SLC12A1Phase 4Fluid OverloadApr 2027
Copenhagen University Hospital, RigshospitaletFurosemide
Sodium-(potassium)-chloride cotransporter 2 inhibitor
SLC12A1Phase 4Pulmonary EdemaMay 2027
Lakeland Regional Health Systems, Inc.Furosemide
Sodium-(potassium)-chloride cotransporter 2 inhibitor
SLC12A1Phase 4Heart FailureJun 2027
University of AarhusFurosemide
Sodium-(potassium)-chloride cotransporter 2 inhibitor
SLC12A1Phase 4Acute Heart FailureSep 2027
University of DelawareFurosemide
Sodium-(potassium)-chloride cotransporter 2 inhibitor
SLC12A1Phase 4Salt-Sensitivity of Blood PressureJan 2028
University of California, Irvinefurosemide
Sodium-(potassium)-chloride cotransporter 2 inhibitor
SLC12A1Phase 4PreeclampsiaJun 2028
Chiang Mai UniversityFurosemide
Sodium-(potassium)-chloride cotransporter 2 inhibitor
SLC12A1Phase 4Acute Kidney InjuryDec 2028
Instituto de Investigación Sanitaria AragónFurosemide
Sodium-(potassium)-chloride cotransporter 2 inhibitor
SLC12A1Phase 3Acute Heart FailureNov 2026
Stacy JohnsonBumetanide
Sodium-(potassium)-chloride cotransporter 2 inhibitor
SLC12A1Phase 3CirrhosisMar 2029
Sherief Abd-ElsalamBumetanide
Sodium-(potassium)-chloride cotransporter 2 inhibitor
SLC12A1Phase 3AutismDec 2030
Northwestern UniversityFurosemide
Sodium-(potassium)-chloride cotransporter 2 inhibitor
SLC12A1Phase 3BPH With Urinary Obstruction–
University Hospital, ToursFurosemide
Sodium-(potassium)-chloride cotransporter 2 inhibitor
SLC12A1Phase 3Kidney Stone–
Stanford UniversityBumetanide
Sodium-(potassium)-chloride cotransporter 2 inhibitor
SLC12A1Phase 2Alzheimer DiseaseDec 2026
Emory UniversityFurosemide
Sodium-(potassium)-chloride cotransporter 2 inhibitor
SLC12A1Phase 2Prostate AdenocarcinomaJul 2028
Memorial Sloan Kettering Cancer CenterBumetanide
Sodium-(potassium)-chloride cotransporter 2 inhibitor
SLC12A1Phase 1Unresectable Hepatocellular CarcinomaApr 2027
Yale UniversityBumetanide
Sodium-(potassium)-chloride cotransporter 2 inhibitor
SLC12A1Phase 1Heart FailureMay 2027
Yale UniversityBendroflumethiazide
Thiazide diuretic
SLC12A1Phase 1Heart FailureJun 2028

Conditions

Heart Failure (3) Heart Failure, Congestive (3) Acute Heart Failure (3) Fluid Overload (1) Salt-Sensitivity of Blood Pressure (1) Unresectable Hepatocellular Carcinoma (1) BPH With Urinary Obstruction (1) Alzheimer Disease (1) Kidney Stone (1) Acute Kidney Injury (1) Preeclampsia (1) Autism (1)

Modalities

small molecule (20)

Companies

Heart Center Research, LLC (3) Yale University (2) Morten H. Bestle (1) University of Delaware (1) Lakeland Regional Health Systems, Inc. (1) Memorial Sloan Kettering Cancer Center (1) Northwestern University (1) Instituto de Investigación Sanitaria Aragón (1) University of Aarhus (1) Stanford University (1) University Hospital, Tours (1) Chiang Mai University (1) University of California, Irvine (1) Sherief Abd-Elsalam (1) Copenhagen University Hospital, Rigshospitalet (1) Stacy Johnson (1) Emory University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.